ALK+ Anaplastic Large Cell Lymphoma
1 clinical trials · Condition
◉ Watch ALK+ Anaplastic Large Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL (NCT02462538) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2015-11-03 |
Track ALK+ Anaplastic Large Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.